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Octreotide administration in diabetic rats: Effects on renal hypertrophy
and urinary albumin excretion. Initial renal hypertrophy in experimental
diabetes is prevented by administration of a long-acting somatostatin
analogue octreotide (SMS). To investigate the long-term effects of SMS
on renal hypertrophy and urinary albumin excretion (UAE), streptozo-
tocin-diabetic and non-diabetic rats were treated with two daily subcu-
taneous injections of SMS (100 jsg x 2) for six months. Untreated
diabetic and non-diabetic animals were used as reference groups. No
differences were seen between the two diabetic groups in respect to
body weight, food intake, blood glucose levels, urinary glucose output,
hemoglobin A(HbA,), fructosamine, serum growth hormone (rGH)
or creatinine clearance, but kidney weight (896 36 vs. 1000 24 mg,
P < 0.02), UAE (417 131 vs. 1098 187 sg/24 hr, P < 0.02), kidney
insulin-like growth factor I (IGF-I) (167 16 vs. 239 17 nglg, P <
0.01) and serum IGF-l (301 26 vs. 407 17 sg/liter, P < 0.01) were
all reduced in the SMS-treated diabetic animals when compared to the
untreated diabetic group. In non-diabetic rats SMS reduced body
weight (274 3 vs. 293 5g, P < 0.01), kidney weight (695 9 vs. 764
17 mg, P < 0.01), UAE (83 29 vs. 364 114 .tg/24 hr, P < 0.02),
kidney IGF-I (202 12 vs. 280 12 ng/g, P < 0.01), serum IGF-I (428
21 vs. 601 54 rg/liter, P < 0.01) and serum rGH (67 6 vs. 126
27 sgIliter, P < 0.05) when compared to untreated controls. When
kidney weights were expressed in relation to body weight no difference
was found between SMS-treated and untreated controls, while the
difference between SMS-treated and untreated diabetic animals was
still present (P < 0.01). In conclusion, chronic administration of SMS
has abating effects on diabetic renal hypertrophy and UAE, and thus
indicates that SMS may reduce development of diabetic kidney lesions
in experimental diabetes. The long-term suppressive effects of SMS on
renal enlargement and UAE may in part be mediated through iceduction
in circulating and kidney IGF-I levels.
A variety of clinical and experimental studies dealing with
diabetes mellitus have been designed and conducted in an
attempt to characterize the mechanisms underlying the in-
creases in kidney size, glomerular volume and kidney function
and the later developing increase in urinary albumin excretion
(UAE) and kidney lesions associated with diabetes. The search
for significant pathogenic mechanisms in diabetic kidney dis-
ease has been focused on the early events in which renal and
glomerular hypertrophy and hyperfunction take place. Induc-
tion of streptozotocin (STZ)-diabetes in rats causes a rapid
increase in renal and glomerular size regularly demonstrable
within the first week after the injection of STZ [1—3]. Interest-
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ingly, the early renal hypertrophy taking place within the first
weeks after induction of diabetes [1—3] is of about the same
magnitude as that found after six months [4]. Studies of UAE in
experimental diabetes have shown increased values after few
weeks of diabetes with a steady increase that continues with
diabetes duration [5, 61.
Although growth hormone (rGH) secretion in STZ-diabetic
rats is inhibited [7] rather than paradoxically stimulated as seen
in human diabetes [8], experiments from our laboratories have
suggested a causative role for insulin-like growth factor I
(IGF-I) in initial renal hypertrophy in experimental diabetes
[9—131. The initial renal hypertrophy is preceded by a rise in the
kidney IGF-I content, which reaches a peak 24 to 48 hours after
induction of diabetes [9—13], and strict insulin treatment abol-
ishes both the increase in kidney IGF-I and renal size [9, 131.
Furthermore, administration of a long-acting somatostatin ana-
logue octreotide (SMS) has an equally inhibitory effect on
kidney IGF-I accumulation and growth [10] and without affect-
ing the blood glucose levels, supports the hypothesis that renal
IGF-I accumulation is a prerequisite for initial diabetic kidney
growth.
In the present study we examined the possible long-term
effects of SMS on renal hypertrophy, UAE, kidney IGF-I,
serum IGF-I and rGFI levels in STZ-diabetic rats treated with
SMS for six months.
Methods
Study Design
Four groups of adult female Wistar rats (MØllegaards AvIs-
lab., Eiby, Denmark) with initial body weights of 165 to 187
grams were studied. Rats were housed three to four per cage in
a room with 12:12 hour (06.00 to 18.00 hours) artificial light
cycle, temperature 21 2°C and humidity 55 2%. The
animals had free access to standard chow (Altromin # 1324,
Lage, Germany) and tap water throughout the experiment. The
animals were randomized into four groups; two of these groups
were made diabetic by an i.v. injection of STZ (Upjohn Com-
pany, Kalamazoo, Michigan, USA) in a dose of 55 mg/kg body
weight, under sodium barbital anesthesia (50 mg/kg). Blood
glucose was measured 1, 2, 3 and 7 days after the STZ injection,
and the urine tested for glucose and ketone bodies by Neostix-4
(Ames, Stoke Poges, Slough, UK). Only animals with blood
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glucose levels above 18 mmollliter, urine glucose concentration
above 111 mmollliter and without ketonuria were included in
the study.
One non-diabetic group and one diabetic group were treated
with subcutaneous injections of SMS (Sandostatin, Sandoz,
Ltd., Basle, Switzerland). The treatment was started immedi-
ately after STZ injection and was given in a dose (100 sg twice
daily) large enough to maintain high diurnal serum concentra-
tions (that is, above 1000 ng/liter) [10]. Untreated diabetic and
non-diabetic control rats were not injected with vehicle but all
animals were handled every day and had their cages cleaned.
One week before the experiment started and monthly there-
after the animals were placed in individual metabolic cages for
21hour urine collections (for determination of urinary glucose,
creatinine and albumin excretion) and measurements of food
consumption. In addition, body weight and blood glucose were
recorded monthly and urine tested for ketonuria. By the end of
the study period the animals were anesthetized with sodium
barbital (50 mg/kg) and blood was drawn from the retro-orbital
venous plexus for hemoglobin A1 (HbA1) determination and
for determination of fructosamine, sodium (Na), potassium (K),
creatinine, rGH, IGF-I and insulin in serum. Serum was stored
at —80°C until measurements were performed. Furthermore,
the left kidneys were rapidly removed and carefully cleaned,
weighed, and snap-frozen in liquid nitrogen for later determi-
nation of kidney IGF-I content.
Determination of metabolic parameters
3lood and urinary glucose concentration. Blood glucose was
measured in tail vein blood by Haemoglucotest 1-44 and Re-
flolux II reflectance meter (Boehringer-Mannheim, Mannheim,
Germany). Urinary glucose concentration was measured in
24-hour urine collections by standard glucose oxidase tech-
nique.
Determination of HbAIC and fructosamine. HbAIC was
determined using affinity chromatography on columns (Bio-Rad
Hemoglobin A1, Micro Column Test, Richmond, California,
USA). Under sodium barbital anesthesia (50 mg/kg) 100 d
blood was withdrawn from the retro-orbital sinus into heparin-
ized tubes and centrifuged. The plasma was separated from the
red blood cells immediately and the blood cells were washed in
500 l 0.154 M NaC1. After lysation in 1 ml distilled water the
hemolysate was eluted on resin columns, and both the HbAIC
and total hemoglobin concentrations were recorded at 415 nm in
a spectrophotometer.
Reagents and standards for the fructosamine assay were
purchased from Hoffmann-La Roche, Basle, Switzerland (Fruc-
tosamine Test Plus) and the determination performed as previ-
ously described [14]. The principle of the assay relies on the
reducing potential of ketoamines in alkaline medium. The
serum fructosamine assay measurements all glycated serum
proteins by forming the corresponding eneaminols, which in
turn reduce nitroblue tetrazolium to the colored formazan
derivative. The rate of formazane color development correlates
with the fructosamine level [14].
Urinary albumin excretion, electrolytes and creatinine
clearance
Urinary albumin excretion (UAE). The urinary albumin con-
centration in 24-hour urine collections was determined by
radioimmunoassay as previously described [15] using rat albu-
min antibody and standards. The urine samples were stored at
—20°C until assay was performed. Rabbit anti-rat albumin
antibody RARa/AIb was purchased from Nordic Pharmaceuti-
cals and Diagnostics (Tilburg, The Netherlands). For standard
and iodination a globulin-free rat albumin was obtained from
Sigma Chemical Co. (St. Louis, Missouri, USA).
Measurements of serum sodium (Na), potassium (K), creat-
mine and urinary creatinine concentration. Serum Na and K
were measured using conventional laboratory techniques. Se-
rum and urinary creatinine concentrations (in 24-hr urine col-
lections) were measured by an automated technique adapted
from the method of Jaffe and corrected for the prevailing
glucose contents (because of interference in the Jaffe reaction).
Creatinine clearance was expressed in mllmin.
Hormonal measurements
IGF-I extraction from kidney and IGF-I radioimmunoassay.
Kidney IGF-I extraction was performed according to D'Ercole,
Stiles and Understood [16] as previously described [9—13].
Briefly, the kidneys were homogenized on ice in 1 M acetic acid
(5 ml/g kidney) with an Ultra Turrax TD 25 (Janke-Kunkel
GmbH, Stauten, Germany) and further disrupted using a Potter-
Elvehjelm homogenizer. The tissues were extracted twice, and,
after lyophilization, the samples were redissolved in 40 mM
phosphate buffer (pH 8.0) with 0.2% BSA (Sigma Chemical
Co.). Tissue extracts were kept at —80°C until IGF-I assay was
performed within two to three weeks after extraction, When
kidney extracts were lyophilized and assayed in the presence of
biosynthetic IGF-I the mean recovery of added IGF-I was 101%
(range 84 to 115). As previously described the kidney IGF-I
concentration was corrected for the contribution of entrapped
plasma IGF-I [17].
IGF-I antibody UB 286 (raised by L.E. Underwood and J.J.
van Wyk, Pediatric Endocrinology, University of North Caro-
lina, Chapel Hill, North Carolina, USA) was donated by the
U.S. National Hormone and Pituitary Program. For standard
(0.5 to 10 pg/liter) and iodination a full amino acid sequence
IGF-I analogue (Amgen Biologicals, California, USA) was
purchased from Amersham International (Amersham, Bucks,
UK). IGF-I was measured in rat serum after extraction in
methanol-acetic acid as previously described [9—13]. Intraassay
coefficient of variance (CV) on dublicates was 5%, and interas-
say CV was 12% (N = 10). The IGF-I antibody has 0.5% cross
reactivity with IGF-II and cross reacts minimally with insulin at
106 M.
Determination of rat OH and insulin. Serum rGH and insulin
were measured by radioimmunoassay as previously described
118, 19]. In the rat insulin assay a detection limit of 0.5 mU/liter
was achieved by using a two-phase incubation scheme.
Statistical analysis
All results are given as mean values SEM. Differences
between groups were analyzed by one-way analysis of variance
in combination with the Bonferroni test for multiple compari-
sons and unpaired Student's t-test. Student's I-test for paired
samples was used to compare UAE at the beginning and
throughout the time course of the study.
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Fig. 1. Changes in body weight (A) and food
consumption (B) over six months in non-
diabetic animals with (• •; N = 16)
or without SMS administration (0—0;
N 14) and in diabetic animals with
(A A; N = 10) or without SMS
____________________________
administration (tx—i; N 11). Each point
represents mean values with vertical bars
0 60 1 20 180 denoting SEM. Statistical significance level for
differences between SMS treated and untreated
Time, days non-diabetic animals is indicated by: * < 0.01.
Results
Body weight and food consumption
Figure 1 shows the monthly measurements of body weight
and food consumption in the four experimental groups. As
illustrated in Figure 1A, body weight gains in SMS-treated and
untreated diabetic animals were reduced compared to non-
diabetic groups (P < 0.01). However, both diabetic groups grew
steadily, albeit slowly, throughout the six months studied (Fig.
IA) and no differences were found at any time between the two
groups. In contrast, SMS-treatment of non-diabetic animals
induced a body weight gain reduction, statistically significant
from month 3 and onwards (P < 0.01). Food consumption
expressed as g/24 hr was increased by approximately 60% in
both diabetic groups when compared to non-diabetic groups
(Fig. 1 B). SMS-treatment did not affect the food intake in either
diabetic or non-diabetic animals (Fig, 1A).
Metabolic control
The blood glucose levels were markedly elevated in the two
diabetic groups with mean values between 25and 30 mmol/liter
throughout the study period (Fig. 2A). To be able to estimate an
effect of SMS on metabolic control the blood glucose measure-
ments in all groups were performed approximately one hour
after the subcutaneous SMS injection. No differences were
found in blood glucose levels between the two diabetic groups,
however, in the SMS-treated non-diabetic animals a small but
consistent elevation in blood glucose concentrations was seen
one hour after the SMS injection (Fig. 2A). However, this effect
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Fig. 2. Changesin blood glucose (A) and
urinary glucose output (B) oversix months in
non-diabetic animals with (• S) or
without SMS administration (0—0) and in
diabetic animals with (A A) or
without SMS administration (s—A). Data
are means SEM with the number of animals
in the four different groups as indicated in
Fig. 1. Statistical significance level for
differences between SMS treated and
untreated non-diabetic animals is indicated by:
* <0.01.
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Table 1. Hemoglobin A1 (HbA1) and serum fructosamine after six
months in control and diabetic animals with or without SMS
administration
Experimental
groups
HbAIC
%
Fructosamine
pmo!/liter
Controls 1.4 0.1 260 11
(N = 14)
Controls + SMS 1.4 0.1 268 7
(N = 16)
Diabetic 2.2 0.l 321 8
(N= II)
Diabetic + SMS 2.3 0.2a 323 l4
(N = 10)
Values are mean SEM.
a p < 0.01, compared to non-diabetic control groups
on blood glucose levels was not detectable ten to twelve hours
after the SMS injection (data not shown). Figure 2B shows the
monthly measurements of the urinary glucose output. Unde-
tectable urinary glucose concentrations were found in the
non-diabetic groups, and no differences were found in the
urinary glucose excretion between the SMS treated and the
untreated diabetic groups (Fig. 2B) with mean values around 40
mmol glucose/24 hr. SMS treatment did not affect urine pro-
duction over 24 hours in either non-diabetic or diabetic animals
at any time throughout the study period (data not shown).
HbAIC and serum fructosamine levels by the end of the study in
the four experimental groups are given in Table 1. Marked
elevations were found in both parameters in the two diabetic
groups amounting to mean increases of 60% and 22%, respec-
tively, when compared to non-diabetic control groups (Table 1).
Furthermore, SMS treatment had no effect on HbAIC or
fructosamine levels in either of the treated groups when com-
pared to untreated groups (Table 1). The recorded HbAIC levels
are lower than those observed in healthy and diabetic humans,
but in accordance with a previous report in mice [20].
Kidney weight
Figure 3 gives the kidney weights after six months with or
without SMS treatment in the four experimental groups. The
kidney weight increase in the untreated diabetic group
amounted to 31% when compared to non-diabetic controls
(1000 24 vs. 764 17 mg, P < 0.01). The kidney weight
increase was diminished in the SMS-treated diabetic animals
when compared to untreated diabetic animals (896 36 vs. 1000
24 mg, P < 0.02) and amounted to only 17% when compared
to non-diabetic controls (P < 0.01). In addition, the kidney
weight was reduced in the SMS treated controls when com-
pared to untreated controls (695 9 vs. 764 17 mg, P < 0.01).
However, when the kidney weights were expressed as kidney
weight/body weight no difference was found between SMS
treated and untreated controls (0.0025 0.0001 vs. 0.0026
0.0001, NS), while the difference between SMS treated and
untreated diabetic animals was still present (0.0040 0.0001 vs.
0.0044 0.0001, P < 0.01).
Urina,y albumin excretion
Monthly consecutive values for 24 hour UAE in the four
experimental groups are depicted in Figure 4, Non-diabetic
control animals exhibited minimal UAE at the beginning of the
study, but developed as previously described [6, 211 a modest
degree of age-related increase in urinary albumin excretion
during study (P < 0.01 Fig. 4). Untreated diabetic animals
exhibited a marked elevation in UAE which significantly in-
creased (P < 0.01) as early as one month after induction of
diabetes followed by a slower further increase over time (Fig.
4). Throughout the whole study period UAE in the SMS-treated
diabetic group remained significantly lower when compared to
the untreated diabetic rats, with values comparable to untreated
non-diabetic control rats (Fig. 4). In addition, SMS-treatment in
non-diabetic rats totally abolished the age-related increase in
UAE (Fig. 4).
Serum electrolytes and kidney function
Table 2 shows serum sodium (Na), potassium (K), creatinine
levels and creatinine clearances by the end of the study. No
differences in serum Na or creatinine were found between the
four groups, while serum K was decreased in the untreated
diabetic group when compared to both SMS treated diabetic
and non-diabetic groups (Table 2). Both diabetic groups exhib-
ited increased creatinine clearance when compared to their
respective non-diabetic control groups and no differences were
found between SMS treated and untreated groups (Table 2).
Serum rGH, insulin, IGF-I and kidney IGF-I
Table 3 shows serum rGH, insulin, IGF-I and kidney IGF-I
levels in the four experimental groups by the end of the study.
It has been shown previously that barbital anesthesia induces
an increase in GH levels in rats lasting longer than 90 minutes
[221, and it follows, therefore, that the rGH levels given in Table
3 are stimulated values. Reduced rGH levels amounting to 48%
were seen in response to the diabetic state per Se, when
comparing untreated diabetic animals to untreated controls
(Table 3). In addition, a reduction in rGH levels to values
comparable to those seen in untreated diabetic animals (Table
3) was seen in response to SMS treatment of non-diabetic
animals. In SMS-treated diabetic animals there was a tendency
to decreased rGH levels when compared to untreated diabetic
animals, but the difference did not reach statistical significance
(Table 3). The changes in serum IGF-I levels in the four
experimental groups followed the same pattern as that seen in
serum rGH. SMS treatment in non-diabetic animals reduced
serum IGF-I by 29%, to levels comparable to the decreased
levels induced by the diabetic state itself (Table 3). SMS
treatment in diabetic animals, however, caused a further reduc-
tion in serum IGF-I amounting to 26% when compared to
untreated diabetic animals (Table 3). Kidney 10 F-I levels by the
end of the study (expressed as ng/g kidney) are shown in Table
3. The concentrations shown are all corrected for contribution
of plasma IGF-I (Methods). SMS treatment in non-diabetic
animals reduced kidney IGF-I by 28% (from 280 13 to 202
12 ng/g, P < 0.01; Table 3). Despite the reduction observed in
serum IGF-I in untreated diabetic animals, no difference was
found in kidney IGF-I levels between non-diabetic and diabetic
animals. However, when diabetic animals were treated with
SMS a reduction amounting to 30% was seen (239 17 vs. 167
16 ng/g, P < 0.01) when compared to untreated diabetic
animals (Table 3). Finally, Table 3 gives the serum insulin levels
by the end of the study in the four experimental groups. As
expected, very low insulin levels were found in both diabetic
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Fig. 4. Changes in urinary albumin excretion
over six months in non-diabetic animals with(• I) or without SMS-administration(O—O) and in diabetic animals with
(A A) or without SMS-administration(A—). Data are means SEM and the
number of animals in the four different groups
are as indicated in Fig. 1. < 0.05, SMS
0 1 2 3 4 5 6 treated non-diabetic animals compared to all
other groups and untreated diabetic animals
Time, months compared to all other groups.
groups when compared to the values seen in non-diabetic
animals, and it is noteworthy that there was no detectable effect
of SMS on the insulin levels (Table 3).
Discussion
The suggestion that SMS may have sustained action on
kidneys in long-term diabetic animals arose from the previous
observation that SMS treatment abolishes the early transient
increase in kidney IGF-I concentration as well as the initial
diabetic renal hypertrophy seen in short-term diabetes [10, 23].
The present study demonstrates reduction in diabetic renal
hypertrophy, serum IGF-I, kidney IGF-I and maintenance of
normal UAE in diabetic rats treated with SMS for six months.
The animals in the present study received SMS doses twice
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Table 2. Serum sodium (Na), potassium (K), creatinine and
creatinine clearance after six months in control and diabetic animals
with or without SMS administration
Experimental
groups
Na K
mmol/liter
Creatinine
p.mo!/Iiter
Creatinine
clearance
mi/mm
Controls 145 4 4.4 0.1 53 2 0.70 0.10
(N = 14)
Controls + SMS 149 2 4.6 0.1 53 2 0.55 0.11
(N = 16)
Diabetic 144 2 4.0 0.la 57 3 1.10 0.08k
(N= 11)
Diabetic + SMS 146 2 4.5 0.1 55 2 1.00 O,ll
(N = 10)
Values are mean SEM.
a p < 0.05, compared to all other groups
P < 0.05, compared to non-diabetic control groups
Table 3. Serum rat growth hormone (rGH), serum insulin-like growth
factor I (IGF-I), kidney IGF-I and serum insulin after six months in
control and diabetic animals with or without SMS administration
Experimental
groups
rGH IGF-1 Kidney
IGF-I
ng/g kidney
Insulin
mu/literp.g/liter
Controls 125 27 601 54b 280 13C 10 5
(N = 14)
Controls + SMS 67 6 428 21 202 12 14 3
(N = 16)
Diabetes 65 10 407 17 239 17 0.4 0.3a
(N= II)
Diabetes + SMS 44 8 301 26 167 16d 0.3 0.2(N = 10)
Values are means SEM.
a p < 0.05 and b p < 0.01, compared to all other groups
P < 0.01, compared to SMS-treated controls and SMS-treated
diabetic animals
d P < 0.01, compared to untreated controls and diabetic animals
a P < 0.01, compared to non-diabetic controls
daily large enough to maintain high diurnal serum levels [10].
The persistent effects of the SMS treatment are evident from
the suppressed serum rGH and IGF-I levels and from the
reduced kidney IGF-I concentrations observed in the SMS
treated groups at the end of the study. Furthermore, we
observed no toxic (such as, anorexic) effect of SMS treatment,
that is, no influence on body weight (only diabetic animals),
food consumption, metabolic control or mortality. The fact that
we did not find a further growth retardation in SMS-treated
diabetic animals is possibly due to the pronounced decrease in
serum rGH already induced by the diabetic state perse. No
measurable effect of SMS treatment was seen on food consump-
tion, serum insulin, urinary glucose output, HbAIC or serum
fructosamine indicating that the effect of SMS on the carbohy-
drate metabolism is negligible.
In accord with previous studies, untreated diabetic rats in the
present study exhibited marked and progressive albuminuria
and renal hypertrophy within a diabetes duration of six months
[4—61. In sharp contrast to these findings SMS treatment in
diabetic rats was associated with a smaller increase in UAE
with time, never reaching values significantly different from
values in non-diabetic controls. SMS also induced a pro-
nounced reduction in the increase in UAE seen in non-diabetic
rats with advancing age. This implies that the effect of SMS
observed in diabetic rats does not necessarily ameliorate the
functional aberration specific for diabetes. In the present study
SMS treatment diminished the final kidney weight in diabetic
animals, but it did not completely prevent renal hypertrophy.
When kidney weights were expressed in relation to body weight
the SMS induced reduction in kidney size observed in non-
diabetic rats disappeared. This was not the case for diabetic
animals, which may indicate that SMS abolishes only the
diabetes related kidney growth. While UAE and renal size were
diminished in SMS-treated diabetic rats the metabolic control
and food consumption throughout the study remained at iden-
tical stable high levels in both diabetic groups. HbAIC and
fructosamine at the end of the study were also essentially
identical in the diabetic groups, and well in excess of values
seen in both control groups. Thus the observed differences
between SMS treated and untreated diabetic groups regarding
UAE and renal hypertrophy could not be attributed to im-
proved metabolic control in the former.
Very similar observations have been made in STZ-diabetic
rats receiving long-term treatment with ACE inhibitors [24], but
it is not known whether this treatment has any effect on IGF-I
levels, circulating or local. It is interesting that neither treat-
ment seemed to influence metabolic control as demonstrated
here for SMS, because it is firmly established that glycemic
control is the prime responsible factor in development of
diabetic kidney hypertrophy and hyperfunction [25, 261. So it is
suggested that SMS (and ACE inhibitors) play their roles at
some later step(s) in the partly unknown sequence of events
initiating and maintaining diabetic kidney hypertrophy.
Clinical studies in healthy and diabetic subjects have demon-
strated that both native somatostatin [27] and SMS [28] have
impressive acute suppressive effects on renal function [glomer-
ular filtration rate (GFR) and renal plasma flow (RPF)]. SMS
might exert the same effects on hemodynamics in diabetic rats,
but to our knowledge no reports on this topic have been
published. However, in a recent paper short-term somatostatin
infusion to non-diabetic animals did not affect renal function
[29]. Furthermore, SMS treatment in the present study did not
reduce the diabetic renal hyperfiltration after six months as far
as can be judged from creatinine clearance determinations.
Creatinine clearance was employed in the present study as a
measurement of kidney function, because the reliable constant
infusions technique was feared to reduce the quality of materi-
als to be used for hormonal analysis.
Several hormonal factors have been proposed to be impli-
cated in the hypertrophy-hyperfiltration syndrome of diabetes.
Glucagon has recently received interest because imperfectly
controlled experimental [30] and human diabetes [31] is char-
acterized by elevated plasma glucagon levels. Furthermore,
glucagon administration to normal and diabetic subjects [32, 33]
and rats [341 is followed by an increase in GFR. It is interesting
that the acute suppressive effect of SMS on renal function in
diabetic humans correlated to the decrease in plasma glucagon
[28], but it is unknown whether either of these relationships
persist in more chronic conditions. In addition to these effects
of glucagon on kidney function a relationship between the early
increase in plasma glucagon and renal size in diabetic rats has
been suggested [35]. However, in other experiments in strictly
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metabolically controlled diabetic rats 1361 directed at elucidat-
ing the role of diabetic hyperglucagonaemia in protein wasting,
glucagon administration for up to four weeks to achieve diabetic
portal glucagon levels did not promote kidney growth, indicat-
ing that glucagon does not play a major role in diabetic kidney
hypertrophy.
OH and IGF-I have also been increasingly implicated as
possible mediators of diabetic renal hypertrophy and function.
The infusion of IGF-I in animals [291 and humans [37] has been
shown acutely to increase both GFR and RPF, pointing to a
direct effect of IGF-I on kidney function independent of pri-
mary changes in kidney size. In addition several studies have
shown that IGF-I in hypophysectomized [38], dwarf [39] and
pituitary intact animals [40] within days to weeks is capable of
inducing renal growth. The existence of 1) distinct receptors for
IGF-I in renal glomeruli and tubules [41, 42] and 2) IGF-I
messenger RNA expression in all parts of the nephron [43]
indicates that IGF-I may affect the kidney in both an endocrine
and autocrine/paracrine fashion. In a novel approach, it was
shown that transgenic expression in non-diabetic mice of GH or
IGF-I for 14 to 37 weeks induced enlarged kidney and glomer-
ular size [44, 45], and in those expressing GH mesangial growth
and glomerular changes occurred, claimed to be similar to those
seen in diabetic glomeruloscierosis. Whether or not IGF-1 was
locally accumulated in the kidneys from these animals was not
investigated, but it is not unlikely as we have observed that the
kidney growth of hypophysectomized rats treated with OH is
preceded by a transient increase in renal IGF-I content [46].
The same phenomenon of a transient increase in kidney IGF-I
content is seen in initial diabetic hypertrophy, and there is
increasing evidence that this very early local IGF-I accumula-
tion is a prerequisite for diabetic renal hypertrophy [9—13].
Furthermore, as mentioned above, both the kidney IGF-I
accumulation and the initial renal hypertrophy in diabetic
animals are abolished by SMS administration [10]. In the
present study, serum IGF-I levels were 29% lower in untreated
diabetic animals in comparison to non-diabetic controls at six
months. This decrease in serum IGF-I is usually observed in
untreated experimental diabetes of more than one weeks dura-
tion. SMS administration in non-diabetic animals induced a 29%
decrease in serum IGF-I and a further 26% decrease in diabetic
animals. In addition, SMS administration reduced kidney IGF-1
levels by 28% in non-diabetic and 30% in diabetic animals, in
comparison to their respective controls. As OH secretion is
already drastically reduced in untreated diabetic rats [7], this
confirms previous suggestions that SMS directly inhibits IGF-I
formation independent of OH [10, 17]. Whether the depressive
effect of long-term SMS treatment on serum and kidney IGF-I
bears any causal relationship to the effect of SMS on renal size
and UAE is unknown. It is intriguing, however, that the effects
of SMS on serum IGF-I were observed not only in diabetic but
also in non-diabetic animals, as were the effects on renal IGF-1
content.
In long-term clinical studies in diabetic subjects SMS treat-
ment has been reported to reduce or normalize microalbumin-
uria in diabetic patients over a period of six months [47].
Furthermore, reduced renal hyperfunction and renomegaly was
seen in a group of Type 1 diabetic patients treated with SMS for
a period of three months, without discernible reductions in
serum OH, glucagon or HbAIC, but with pronounced reduc-
tions in circulating IGF-I levels [48]. These clinical results are
largely similar to those obtained in the present study in exper-
imental diabetes.
In conclusion, chronic administration of SMS to diabetic rats
has inhibitory effects on diabetic UAE, renal hypertrophy,
serum and kidney IGF-I, without affecting metabolic control or
renal function. The mechanism of the suppressive effects of
SMS on the diabetic kidney changes may be based on effects of
the decreased circulating and renal concentrations of IGF-1.
The present study and several others suggest that IGF-I is a
factor that should be recognized among the many proposed
physical, biochemical and hormonal candidates in the develop-
ment of diabetic nephropathy and that inhibition of its partici-
pation may be rewarded.
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